Bay State Biotech Report: Amgen’s Cholesterol Drug

Amgen’s cholesterol drug is cutting heart risks less than investors had hoped, and that’s also bad news for companies making similar drugs. That’s all on the Bay State Biotech Report, where Bloomberg biotechnology reporter Doni Bloomfield and Boston radio host Anne Mostue discuss the latest in biotech news from the Boston area and across the nation.

producer: Anne Mostue +1-617-210-4662 or amostue@bloomberg.net.

Running time 01:14

Play Episode
Before it's here, it's on the Bloomberg Terminal. LEARN MORE